Trials / Completed
CompletedNCT05305456
Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Tanreqing Capsule Efficacy and Safety in the Treatment of COVID-19 (Mild and Common Type)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 480 (actual)
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was conducted in a randomized, double-blind, placebo-controlled, multicenter clinical trial design. Two groups were designed, the experimental group and the placebo control group. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit.
Detailed description
The purpose of this study was to evaluate the efficacy and safety of Tanreqing capsule in the treatment of mild and common COVID-19. The trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial design. A total of 480 patients were divided into 2 groups: experimental group and control group 3:1. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tanreqing capsule | 3 capsules per time, 3 times a day |
| DRUG | Tanreqing capsule simulator | 3 capsules per time, 3 times a day |
Timeline
- Start date
- 2022-03-28
- Primary completion
- 2022-06-02
- Completion
- 2022-08-31
- First posted
- 2022-03-31
- Last updated
- 2022-12-06
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05305456. Inclusion in this directory is not an endorsement.